Merck KGaA (FRA:MRK) has been given an average rating of “Hold” by the twenty ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is €100.53 ($116.89).
Several research firms recently issued reports on MRK. DZ Bank reiterated a “neutral” rating on shares of Merck KGaA in a report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, April 15th. Barclays set a €82.00 ($95.35) price objective on Merck KGaA and gave the stock a “sell” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 13th. Finally, UBS Group set a €104.00 ($120.93) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 13th.
MRK stock opened at €91.96 ($106.93) on Friday. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72). The business has a 50-day moving average price of €91.15.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: How are the companies in the S&P 500 selected?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.